Gilead, Regeneron, AstraZeneca and more encourage FDA to expand patient reported outcome guidance

More than a half dozen top drugmakers recently called on the FDA to expand its thinking on patient reported outcomes in cancer trials to include more information on PROs in open-label and single arm trials, which are common in oncology, and to consider the ramifications of sponsors collecting PRO data early in a drug’s development process.